{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:11:23Z","timestamp":1790115083190,"version":"4.0.1"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-05012-6","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T14:08:20Z","timestamp":1775916500000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The role of mesenchymal stem cells in IgA nephropathy: current evidence and future directions"],"prefix":"10.1186","volume":"17","author":[{"given":"Yuqi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiewei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenmin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingqian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianbiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"issue":"1","key":"5012_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12882-024-03555-5","volume":"25","author":"O Zaidi","year":"2024","unstructured":"Zaidi O, Du F, Tang Z, Bhattacharjee S, Pareja K. Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries. BMC Nephrol. 2024;25(1):136.","journal-title":"BMC Nephrol"},{"issue":"6","key":"5012_CR2","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s40620-025-02261-1","volume":"38","author":"L Xu","year":"2025","unstructured":"Xu L, Wu C, Li G. Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review. J Nephrol. 2025;38(6):1557\u201364.","journal-title":"J Nephrol"},{"issue":"6","key":"5012_CR3","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/ndt\/gfae252","volume":"40","author":"X Shen","year":"2025","unstructured":"Shen X, Chen P, Liu M, Liu L, Shi S, Zhou X, et al. Long-term outcomes of IgA nephropathy in China. Nephrol Dial Transpl. 2025;40(6):1137\u201346.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"5012_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, et al. Long-Term Outcomes in IgA Nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727\u201338.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"5012_CR5","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1056\/NEJMra2014530","volume":"385","author":"S Hariharan","year":"2021","unstructured":"Hariharan S, Israni AK, Danovitch G. Long-Term Survival after Kidney Transplantation. N Engl J Med. 2021;385(8):729\u201343.","journal-title":"N Engl J Med"},{"issue":"6","key":"5012_CR6","first-page":"e8789","volume":"12","author":"JC Stanley","year":"2020","unstructured":"Stanley JC, Deng H. Progress in Pathogenesis of Immunoglobin A Nephropathy. Cureus. 2020;12(6):e8789.","journal-title":"Cureus"},{"issue":"1","key":"5012_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","volume":"9","author":"E Stamellou","year":"2023","unstructured":"Stamellou E, Seikrit C, Tang SCW, Boor P, Tesar V, Floege J, et al. IgA nephropathy. Nat Rev Dis Primers. 2023;9(1):67.","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"5012_CR8","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1093\/ndt\/gfm346","volume":"22","author":"BD Oortwijn","year":"2007","unstructured":"Oortwijn BD, Rastaldi MP, Roos A, Mattinzoli D, Daha MR, van Kooten C. Demonstration of secretory IgA in kidneys of patients with IgA nephropathy. Nephrol Dial Transpl. 2007;22(11):3191\u20135.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"5012_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/ndt\/gfm492","volume":"23","author":"JJ Zhang","year":"2008","unstructured":"Zhang JJ, Xu LX, Liu G, Zhao MH, Wang HY. The level of serum secretory IgA of patients with IgA nephropathy is elevated and associated with pathological phenotypes. Nephrol Dial Transpl. 2008;23(1):207\u201312.","journal-title":"Nephrol Dial Transpl"},{"key":"5012_CR10","doi-asserted-by":"publisher","first-page":"1438683","DOI":"10.3389\/fimmu.2025.1438683","volume":"16","author":"K Yao","year":"2025","unstructured":"Yao K, Zheng L, Chen W, Xie Y, Liao C, Zhou T. Characteristics, pathogenic and therapeutic role of gut microbiota in immunoglobulin A nephropathy. Front Immunol. 2025;16:1438683.","journal-title":"Front Immunol"},{"key":"5012_CR11","doi-asserted-by":"publisher","first-page":"819646","DOI":"10.1155\/2011\/819646","volume":"2011","author":"T Kajiyama","year":"2011","unstructured":"Kajiyama T, Suzuki Y, Kihara M, Suzuki H, Horikoshi S, Tomino Y. Different pathological roles of toll-like receptor 9 on mucosal B cells and dendritic cells in murine IgA nephropathy. Clin Dev Immunol. 2011;2011:819646.","journal-title":"Clin Dev Immunol"},{"issue":"1","key":"5012_CR12","doi-asserted-by":"publisher","first-page":"2495836","DOI":"10.1080\/0886022X.2025.2495836","volume":"47","author":"X Huang","year":"2025","unstructured":"Huang X, Chen L, He J, Tang J, Mou Z. Long non-coding RNA in IgA nephropathy: a comprehensive review. Ren Fail. 2025;47(1):2495836.","journal-title":"Ren Fail"},{"key":"5012_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/cells13171460","volume":"13","author":"F Montenegro","year":"2024","unstructured":"Montenegro F, Giannuzzi F, Picerno A, Cicirelli A, Stea ED, Di Leo V, et al. How Stem and Progenitor Cells Can Affect Renal Diseases. Cells. 2024;13:17.","journal-title":"Cells"},{"issue":"1","key":"5012_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12951-023-02257-8","volume":"22","author":"HQ Zhan","year":"2024","unstructured":"Zhan HQ, Zhang X, Chen XL, Cheng L, Wang X. Application of nanotechnology in the treatment of glomerulonephritis: current status and future perspectives. J Nanobiotechnol. 2024;22(1):9.","journal-title":"J Nanobiotechnol"},{"issue":"12","key":"5012_CR15","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1093\/ckj\/sfad164","volume":"16","author":"W Du","year":"2023","unstructured":"Du W, Chen Z, Fang Z, Li J, Weng Q, Zheng Q, et al. Oral glucocorticoids with intravenous cyclophosphamide or oral glucocorticoids alone in the treatment of IgA nephropathy present with nephrotic syndrome and mesangioproliferative glomerulonephritis. Clin Kidney J. 2023;16(12):2567\u201377.","journal-title":"Clin Kidney J"},{"issue":"19","key":"5012_CR16","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, Jha V, Hooi LS, Monaghan H, et al. Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. JAMA. 2022;327(19):1888\u201398.","journal-title":"JAMA"},{"issue":"Suppl 2","key":"5012_CR17","doi-asserted-by":"publisher","first-page":"ii40","DOI":"10.1093\/ckj\/sfad224","volume":"16","author":"F Locatelli","year":"2023","unstructured":"Locatelli F, Del Vecchio L, Ponticelli C. Systemic and targeted steroids for the treatment of IgA nephropathy. Clin Kidney J. 2023;16(Suppl 2):ii40\u20136.","journal-title":"Clin Kidney J"},{"issue":"4","key":"5012_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1681\/ASN.0000000541","volume":"36","author":"J Barratt","year":"2025","unstructured":"Barratt J, Barbour SJ, Brenner RM, Cooper K, Wei X, Eren N, et al. Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA Nephropathy. J Am Soc Nephrol. 2025;36(4):679\u201387.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"5012_CR19","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, Li G, Fu P, Xing G, et al. Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria. Kidney Int Rep. 2023;8(3):499\u2013506.","journal-title":"Kidney Int Rep"},{"issue":"11","key":"5012_CR20","doi-asserted-by":"publisher","first-page":"e70055","DOI":"10.1111\/cts.70055","volume":"17","author":"R Davies","year":"2024","unstructured":"Davies R, Peng SL, Lickliter J, McLendon K, Enstrom A, Chunyk AG, et al. A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF\/APRIL antagonist, in healthy adults. Clin Transl Sci. 2024;17(11):e70055.","journal-title":"Clin Transl Sci"},{"issue":"6","key":"5012_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa2410316","volume":"392","author":"V Perkovic","year":"2025","unstructured":"Perkovic V, Barratt J, Rovin B, Kashihara N, Maes B, Zhang H, et al. Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. N Engl J Med. 2025;392(6):531\u201343.","journal-title":"N Engl J Med"},{"key":"5012_CR22","doi-asserted-by":"publisher","first-page":"922365","DOI":"10.3389\/fmed.2022.922365","volume":"9","author":"M Liu","year":"2022","unstructured":"Liu M, Bian X, Wang L, Li G. The Effect of Hydroxychloroquine on Residual Proteinuria in Patients With Immunoglobulin A Nephropathy: A Retrospective Study Based on Propensity Score Matching. Front Med (Lausanne). 2022;9:922365.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"5012_CR23","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.ekir.2018.03.006","volume":"3","author":"P Yang","year":"2018","unstructured":"Yang P, Zou H, Xiao B, Xu G. Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials. Kidney Int Rep. 2018;3(4):794\u2013803.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"5012_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.kint.2021.04.002","volume":"100","author":"J Barratt","year":"2021","unstructured":"Barratt J, Floege J. SGLT-2 inhibition in IgA nephropathy: the new standard of care? Kidney Int. 2021;100(1):24\u20136.","journal-title":"Kidney Int"},{"issue":"10417","key":"5012_CR25","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077\u201390.","journal-title":"Lancet"},{"issue":"6","key":"5012_CR26","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","volume":"392","author":"HJL Heerspink","year":"2025","unstructured":"Heerspink HJL, Jardine M, Kohan DE, Lafayette RA, Levin A, Liew A, et al. Atrasentan in Patients with IgA Nephropathy. N Engl J Med. 2025;392(6):544\u201354.","journal-title":"N Engl J Med"},{"issue":"6","key":"5012_CR27","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","volume":"105","author":"R Lafayette","year":"2024","unstructured":"Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J, et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024;105(6):1306\u201315.","journal-title":"Kidney Int"},{"key":"5012_CR28","doi-asserted-by":"publisher","first-page":"926517","DOI":"10.3389\/fimmu.2022.926517","volume":"13","author":"J Liao","year":"2022","unstructured":"Liao J, Zhou Y, Xu X, Huang K, Chen P, Wu Y, et al. Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: A comprehensive review. Front Immunol. 2022;13:926517.","journal-title":"Front Immunol"},{"issue":"26","key":"5012_CR29","doi-asserted-by":"publisher","first-page":"e21000","DOI":"10.1097\/MD.0000000000021000","volume":"99","author":"G Ismail","year":"2020","unstructured":"Ismail G, Obrisca B, Jurubita R, Andronesi A, Sorohan B, Vornicu A, et al. Budesonide versus systemic corticosteroids in IgA Nephropathy: A retrospective, propensity-matched comparison. Med (Baltim). 2020;99(26):e21000.","journal-title":"Med (Baltim)"},{"key":"5012_CR30","doi-asserted-by":"publisher","first-page":"114114","DOI":"10.1016\/j.jconrel.2025.114114","volume":"386","author":"S Kim","year":"2025","unstructured":"Kim S, Kim Y, Choi S, Kim MS. Enhanced wound healing via stem cell migration using a substance P1-loaded cross-linked small intestinal submucosa scaffold. J Control Release. 2025;386:114114.","journal-title":"J Control Release"},{"key":"5012_CR31","doi-asserted-by":"publisher","first-page":"8837654","DOI":"10.1155\/2020\/8837654","volume":"2020","author":"D Rady","year":"2020","unstructured":"Rady D, Abbass MMS, El-Rashidy AA, El Moshy S, Radwan IA, Dorfer CE, et al. Mesenchymal Stem\/Progenitor Cells: The Prospect of Human Clinical Translation. Stem Cells Int. 2020;2020:8837654.","journal-title":"Stem Cells Int"},{"issue":"1","key":"5012_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13287-024-03849-3","volume":"15","author":"L Zheng","year":"2024","unstructured":"Zheng L, Chen W, Yao K, Xie Y, Liao C, Zhou T. Clinical and preclinical studies of mesenchymal stem cells to alleviate peritoneal fibrosis. Stem Cell Res Ther. 2024;15(1):237.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5012_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13287-020-02108-5","volume":"12","author":"W Lin","year":"2021","unstructured":"Lin W, Li HY, Yang Q, Chen G, Lin S, Liao C, et al. Administration of mesenchymal stem cells in diabetic kidney disease: a systematic review and meta-analysis. Stem Cell Res Ther. 2021;12(1):43.","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"5012_CR34","first-page":"393","volume":"3","author":"AJ Friedenstein","year":"1970","unstructured":"Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970;3(4):393\u2013403.","journal-title":"Cell Tissue Kinet"},{"issue":"4","key":"5012_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy"},{"key":"5012_CR36","doi-asserted-by":"publisher","first-page":"963689723116425","DOI":"10.1177\/09636897231164251","volume":"32","author":"F Chen","year":"2023","unstructured":"Chen F, Chen N, Xia C, Wang H, Shao L, Zhou C, et al. Mesenchymal Stem Cell Therapy in Kidney Diseases: Potential and Challenges. Cell Transpl. 2023;32:9636897231164251.","journal-title":"Cell Transpl"},{"issue":"17","key":"5012_CR37","doi-asserted-by":"publisher","first-page":"8103","DOI":"10.1111\/jcmm.16830","volume":"25","author":"Y Chen","year":"2021","unstructured":"Chen Y, Shen H, Ding Y, Yu Y, Shao L, Shen Z. The application of umbilical cord-derived MSCs in cardiovascular diseases. J Cell Mol Med. 2021;25(17):8103\u201314.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"5012_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/scrt477","volume":"5","author":"P Swamynathan","year":"2014","unstructured":"Swamynathan P, Venugopal P, Kannan S, Thej C, Kolkundar U, Bhagwat S, et al. Are serum-free and xeno-free culture conditions ideal for large scale clinical grade expansion of Wharton\u2019s jelly derived mesenchymal stem cells? A comparative study. Stem Cell Res Ther. 2014;5(4):88.","journal-title":"Stem Cell Res Ther"},{"issue":"6","key":"5012_CR39","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.4110\/in.2023.23.e48","volume":"23","author":"J Lee","year":"2023","unstructured":"Lee J, Jang J, Cha SR, Lee SB, Hong SH, Bae HS, et al. Recombinant Human Bone Morphogenetic Protein-2 Priming of Mesenchymal Stem Cells Ameliorate Acute Lung Injury by Inducing Regulatory T Cells. Immune Netw. 2023;23(6):e48.","journal-title":"Immune Netw"},{"issue":"11","key":"5012_CR40","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.108.175943","volume":"102","author":"S Dimmeler","year":"2008","unstructured":"Dimmeler S, Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res. 2008;102(11):1319\u201330.","journal-title":"Circ Res"},{"key":"5012_CR41","doi-asserted-by":"publisher","first-page":"1027686","DOI":"10.3389\/fendo.2022.1027686","volume":"13","author":"M Yang","year":"2022","unstructured":"Yang M, Chen J, Chen L. The roles of mesenchymal stem cell-derived exosomes in diabetes mellitus and its related complications. Front Endocrinol (Lausanne). 2022;13:1027686.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"5012_CR42","doi-asserted-by":"publisher","first-page":"910592","DOI":"10.3389\/fcell.2022.910592","volume":"10","author":"J Wang","year":"2022","unstructured":"Wang J, Lin Y, Chen X, Liu Y, Zhou T. Mesenchymal stem cells: A new therapeutic tool for chronic kidney disease. Front Cell Dev Biol. 2022;10:910592.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"5012_CR43","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/stmcls\/sxad089","volume":"42","author":"E Li","year":"2024","unstructured":"Li E, Xu J, Liu N, Xiong Q, Zhang W, Gong Y, et al. Application Potential of Extracellular Vesicles Derived From Mesenchymal Stem Cells in Renal Diseases. Stem Cells. 2024;42(3):216\u201329.","journal-title":"Stem Cells"},{"issue":"8","key":"5012_CR44","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/jbm.a.36428","volume":"106","author":"M Razavi","year":"2018","unstructured":"Razavi M, Hu S, Thakor AS. A collagen based cryogel bioscaffold coated with nanostructured polydopamine as a platform for mesenchymal stem cell therapy. J Biomed Mater Res A. 2018;106(8):2213\u201328.","journal-title":"J Biomed Mater Res A"},{"issue":"1","key":"5012_CR45","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s40824-023-00448-w","volume":"27","author":"C Ryu","year":"2023","unstructured":"Ryu C, Lee M, Lee JY. Mild heat treatment in vitro potentiates human adipose stem cells: delayed aging and improved quality for long term culture. Biomater Res. 2023;27(1):122.","journal-title":"Biomater Res"},{"issue":"12","key":"5012_CR46","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.3390\/cells10123433","volume":"10","author":"BA Bunnell","year":"2021","unstructured":"Bunnell BA. Adipose tissue-derived mesenchymal stem cells. Cells. 2021;10(12):3433.","journal-title":"Cells"},{"issue":"6","key":"5012_CR47","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jcyt.2013.02.006","volume":"15","author":"P Bourin","year":"2013","unstructured":"Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal\/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT). Cytotherapy. 2013;15(6):641\u20138.","journal-title":"Cytotherapy"},{"issue":"2","key":"5012_CR48","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S0002-9440(10)63683-8","volume":"163","author":"MB Rookmaaker","year":"2003","unstructured":"Rookmaaker MB, Smits AM, Tolboom H, Van \u2018t Wout K, Martens AC, Goldschmeding R, et al. Bone-marrow-derived cells contribute to glomerular endothelial repair in experimental glomerulonephritis. Am J Pathol. 2003;163(2):553\u201362.","journal-title":"Am J Pathol"},{"issue":"7","key":"5012_CR49","doi-asserted-by":"publisher","first-page":"e2001689","DOI":"10.1002\/adhm.202001689","volume":"10","author":"C Chang","year":"2021","unstructured":"Chang C, Yan J, Yao Z, Zhang C, Li X, Mao HQ. Effects of Mesenchymal Stem Cell-Derived Paracrine Signals and Their Delivery Strategies. Adv Healthc Mater. 2021;10(7):e2001689.","journal-title":"Adv Healthc Mater"},{"issue":"Suppl 1","key":"5012_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40635-019-0235-4","volume":"7","author":"CH Masterson","year":"2019","unstructured":"Masterson CH, Curley GF, Laffey JG. Modulating the distribution and fate of exogenously delivered MSCs to enhance therapeutic potential: knowns and unknowns. Intensive Care Med Exp. 2019;7(Suppl 1):41.","journal-title":"Intensive Care Med Exp"},{"issue":"1","key":"5012_CR51","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000047856","volume":"169","author":"J Gao","year":"2001","unstructured":"Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 2001;169(1):12\u201320.","journal-title":"Cells Tissues Organs"},{"issue":"2","key":"5012_CR52","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/biomedicines11020445","volume":"11","author":"A Kulesza","year":"2023","unstructured":"Kulesza A, Paczek L, Burdzinska A. The role of COX-2 and PGE2 in the regulation of immunomodulation and other functions of mesenchymal stromal cells. Biomedicines. 2023;11(2):445.","journal-title":"Biomedicines"},{"issue":"1","key":"5012_CR53","doi-asserted-by":"publisher","first-page":"e12712","DOI":"10.1111\/cpr.12712","volume":"53","author":"W Jiang","year":"2020","unstructured":"Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif. 2020;53(1):e12712.","journal-title":"Cell Prolif"},{"key":"5012_CR54","doi-asserted-by":"crossref","unstructured":"Zhou C, Shang S, Zhao J, Yang Y, Shi M, Li P et al. IL-27 modulates mesenchymal stem cell immunoplasticity for enhanced lupus nephritis therapy via the JAK1-STAT1-IDO axis and tryptophan metabolic orchestration. Research (Wash DC). 2025;8:0748.","DOI":"10.34133\/research.0748"},{"key":"5012_CR55","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.2147\/CIA.S259762","volume":"15","author":"Y Bi","year":"2020","unstructured":"Bi Y, Lin X, Liang H, Yang D, Zhang X, Ke J, et al. Human Adipose Tissue-Derived Mesenchymal Stem Cells in Parkinson\u2019s Disease: Inhibition of T Helper 17 Cell Differentiation and Regulation of Immune Balance Towards a Regulatory T Cell Phenotype. Clin Interv Aging. 2020;15:1383\u201391.","journal-title":"Clin Interv Aging"},{"issue":"5","key":"5012_CR56","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3858\/emm.2009.41.5.035","volume":"41","author":"SH Yang","year":"2009","unstructured":"Yang SH, Park MJ, Yoon IH, Kim SY, Hong SH, Shin JY, et al. Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10. Exp Mol Med. 2009;41(5):315\u201324.","journal-title":"Exp Mol Med"},{"key":"5012_CR57","doi-asserted-by":"publisher","first-page":"6458237","DOI":"10.1155\/2019\/6458237","volume":"2019","author":"R Dong","year":"2019","unstructured":"Dong R, Liu Y, Yang Y, Wang H, Xu Y, Zhang Z. MSC-Derived Exosomes-Based Therapy for Peripheral Nerve Injury: A Novel Therapeutic Strategy. Biomed Res Int. 2019;2019:6458237.","journal-title":"Biomed Res Int"},{"issue":"8","key":"5012_CR58","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41581-018-0023-5","volume":"14","author":"Y Shi","year":"2018","unstructured":"Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018;14(8):493\u2013507.","journal-title":"Nat Rev Nephrol"},{"key":"5012_CR59","doi-asserted-by":"publisher","first-page":"8658246","DOI":"10.1155\/sci\/8658246","volume":"2024","author":"Y Wang","year":"2024","unstructured":"Wang Y, Luo P, Wuren T. Narrative Review of Mesenchymal Stem Cell Therapy in Renal Diseases: Mechanisms, Clinical Applications, and Future Directions. Stem Cells Int. 2024;2024:8658246.","journal-title":"Stem Cells Int"},{"issue":"1","key":"5012_CR60","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s13287-021-02391-w","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu Y, Su YY, Yang Q, Zhou T. Stem cells in the treatment of renal fibrosis: a review of preclinical and clinical studies of renal fibrosis pathogenesis. Stem Cell Res Ther. 2021;12(1):333.","journal-title":"Stem Cell Res Ther"},{"key":"5012_CR61","doi-asserted-by":"crossref","unstructured":"Chang HH, Hsu SP, Chien CT. Intrarenal transplantation of hypoxic preconditioned mesenchymal stem cells improves glomerulonephritis through anti-oxidation, Anti-ER stress, anti-inflammation, anti-apoptosis, and anti-autophagy. Antioxid (Basel). 2019;9(1): 2.","DOI":"10.3390\/antiox9010002"},{"issue":"1","key":"5012_CR62","first-page":"85","volume":"30","author":"Y Fang","year":"2012","unstructured":"Fang Y, Tian X, Bai S, Fan J, Hou W, Tong H, et al. Autologous transplantation of adipose-derived mesenchymal stem cells ameliorates streptozotocin-induced diabetic nephropathy in rats by inhibiting oxidative stress, pro-inflammatory cytokines and the p38 MAPK signaling pathway. Int J Mol Med. 2012;30(1):85\u201392.","journal-title":"Int J Mol Med"},{"key":"5012_CR63","doi-asserted-by":"publisher","first-page":"114817","DOI":"10.1016\/j.biopha.2023.114817","volume":"163","author":"Y Pan","year":"2023","unstructured":"Pan Y, Wu W, Jiang X, Liu Y. Mesenchymal stem cell-derived exosomes in cardiovascular and cerebrovascular diseases: From mechanisms to therapy. Biomed Pharmacother. 2023;163:114817.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"5012_CR64","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1186\/s40001-024-01987-1","volume":"29","author":"R Rahimi Darehbagh","year":"2024","unstructured":"Rahimi Darehbagh R, Seyedoshohadaei SA, Ramezani R, Rezaei N. Stem cell therapies for neurological disorders: current progress, challenges, and future perspectives. Eur J Med Res. 2024;29(1):386.","journal-title":"Eur J Med Res"},{"key":"5012_CR65","doi-asserted-by":"publisher","first-page":"835005","DOI":"10.3389\/fimmu.2022.835005","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Huang B, Jin T, Ocansey DKW, Jiang J, Mao F. Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy. Front Immunol. 2022;13:835005.","journal-title":"Front Immunol"},{"issue":"6","key":"5012_CR66","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41423-023-01022-z","volume":"20","author":"N Kadri","year":"2023","unstructured":"Kadri N, Amu S, Iacobaeus E, Boberg E, Le Blanc K. Current perspectives on mesenchymal stromal cell therapy for graft versus host disease. Cell Mol Immunol. 2023;20(6):613\u201325.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"5012_CR67","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-025-02313-9","volume":"10","author":"X Han","year":"2025","unstructured":"Han X, Liao R, Li X, Zhang C, Huo S, Qin L, et al. Mesenchymal stem cells in treating human diseases: molecular mechanisms and clinical studies. Signal Transduct Target Ther. 2025;10(1):262.","journal-title":"Signal Transduct Target Ther"},{"key":"5012_CR68","doi-asserted-by":"crossref","unstructured":"Cheng J, Zhang C. Mesenchymal stem cell therapy: therapeutic opportunities and challenges for diabetic kidney disease. Int J Mol Sci. 2024;25(19): 10540.","DOI":"10.3390\/ijms251910540"},{"issue":"5","key":"5012_CR69","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00281-021-00878-5","volume":"43","author":"RC Monteiro","year":"2021","unstructured":"Monteiro RC, Suzuki Y. Are there animal models of IgA nephropathy? Semin Immunopathol. 2021;43(5):639\u201348.","journal-title":"Semin Immunopathol"},{"key":"5012_CR70","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/IJNRD.S129227","volume":"11","author":"RS Penfold","year":"2018","unstructured":"Penfold RS, Prendecki M, McAdoo S, Tam FW. Primary IgA nephropathy: current challenges and future prospects. Int J Nephrol Renovasc Dis. 2018;11:137\u201348.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"2","key":"5012_CR71","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/path.5658","volume":"254","author":"X Xie","year":"2021","unstructured":"Xie X, Liu P, Gao L, Zhang X, Lan P, Bijol V, et al. Renal deposition and clearance of recombinant poly-IgA complexes in a model of IgA nephropathy. J Pathol. 2021;254(2):159\u201372.","journal-title":"J Pathol"},{"issue":"5","key":"5012_CR72","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/ki.1985.76","volume":"27","author":"H Imai","year":"1985","unstructured":"Imai H, Nakamoto Y, Asakura K, Miki K, Yasuda T, Miura AB. Spontaneous glomerular IgA deposition in ddY mice: an animal model of IgA nephritis. Kidney Int. 1985;27(5):756\u201361.","journal-title":"Kidney Int"},{"issue":"8","key":"5012_CR73","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1681\/ASN.2011121160","volume":"23","author":"K Okazaki","year":"2012","unstructured":"Okazaki K, Suzuki Y, Otsuji M, Suzuki H, Kihara M, Kajiyama T, et al. Development of a model of early-onset IgA nephropathy. J Am Soc Nephrol. 2012;23(8):1364\u201374.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"5012_CR74","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1084\/jem.191.11.1999","volume":"191","author":"P Launay","year":"2000","unstructured":"Launay P, Grossetete B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L, et al. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger\u2019s disease). Evidence for pathogenic soluble receptor-Iga complexes in patients and CD89 transgenic mice. J Exp Med. 2000;191(11):1999\u20132009.","journal-title":"J Exp Med"},{"issue":"4","key":"5012_CR75","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1084\/jem.20112005","volume":"209","author":"L Berthelot","year":"2012","unstructured":"Berthelot L, Papista C, Maciel TT, Biarnes-Pelicot M, Tissandie E, Wang PH, et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med. 2012;209(4):793\u2013806.","journal-title":"J Exp Med"},{"issue":"5","key":"5012_CR76","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1046\/j.1523-1755.1999.00750.x","volume":"56","author":"T Imasawa","year":"1999","unstructured":"Imasawa T, Nagasawa R, Utsunomiya Y, Kawamura T, Zhong Y, Makita N, et al. Bone marrow transplantation attenuates murine IgA nephropathy: role of a stem cell disorder. Kidney Int. 1999;56(5):1809\u201317.","journal-title":"Kidney Int"},{"issue":"1","key":"5012_CR77","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1159\/000049898","volume":"10","author":"T Imasawa","year":"2002","unstructured":"Imasawa T, Utsunomiya Y. Stem cells in renal biology: bone marrow transplantation for the treatment of IgA nephropathy. Exp Nephrol. 2002;10(1):51\u20138.","journal-title":"Exp Nephrol"},{"issue":"11","key":"5012_CR78","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.3727\/096368912X639008","volume":"21","author":"YY Hyun","year":"2012","unstructured":"Hyun YY, Kim IO, Kim MH, Nam DH, Lee MH, Kim JE, et al. Adipose-derived stem cells improve renal function in a mouse model of IgA nephropathy. Cell Transpl. 2012;21(11):2425\u201339.","journal-title":"Cell Transpl"},{"issue":"3","key":"5012_CR79","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.ki.5002300","volume":"72","author":"H Suzuki","year":"2007","unstructured":"Suzuki H, Suzuki Y, Aizawa M, Yamanaka T, Kihara M, Pang H, et al. Th1 polarization in murine IgA nephropathy directed by bone marrow-derived cells. Kidney Int. 2007;72(3):319\u201327.","journal-title":"Kidney Int"},{"issue":"3","key":"5012_CR80","first-page":"609","volume":"29","author":"DW Zhang","year":"2015","unstructured":"Zhang DW, Qiu H, Mei YM, Fu H, Zheng HG. Repair effects of umbilical cord mesenchymal stem cells on podocyte damage of IgA Nephropathy. J Biol Regul Homeost Agents. 2015;29(3):609\u201317.","journal-title":"J Biol Regul Homeost Agents"},{"issue":"1","key":"5012_CR81","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1755-1536-7-4","volume":"7","author":"F Genovese","year":"2014","unstructured":"Genovese F, Manresa AA, Leeming DJ, Karsdal MA, Boor P. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair. 2014;7(1):4.","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"9","key":"5012_CR82","first-page":"5879","volume":"11","author":"F He","year":"2019","unstructured":"He F, Fan M, Jin Y, Wang H, Ding L, Fan J, et al. Sphingosine kinase 1 inhibition decreases the epithelial-mesenchymal transition and ameliorates renal fibrosis via modulating NF-kappaB signaling. Am J Transl Res. 2019;11(9):5879\u201387.","journal-title":"Am J Transl Res"},{"issue":"5","key":"5012_CR83","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/nep.13047","volume":"23","author":"IH Song","year":"2018","unstructured":"Song IH, Jung KJ, Lee TJ, Kim JY, Sung EG, Bae YC, et al. Mesenchymal stem cells attenuate adriamycin-induced nephropathy by diminishing oxidative stress and inflammation via downregulation of the NF-kB. Nephrol (Carlton). 2018;23(5):483\u201392.","journal-title":"Nephrol (Carlton)"},{"issue":"10","key":"5012_CR84","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41419-022-05305-7","volume":"13","author":"S Xu","year":"2022","unstructured":"Xu S, Cheuk YC, Jia Y, Chen T, Chen J, Luo Y, et al. Bone marrow mesenchymal stem cell-derived exosomal miR-21a-5p alleviates renal fibrosis by attenuating glycolysis by targeting PFKM. Cell Death Dis. 2022;13(10):876.","journal-title":"Cell Death Dis"},{"issue":"1","key":"5012_CR85","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s11033-024-09343-6","volume":"51","author":"DM Mekawy","year":"2024","unstructured":"Mekawy DM, Sabry D, Sabry RM, Abozeid NF. Silymarin and MSC-exosomes ameliorate thioacetamide-evoked renal fibrosis by inhibiting TGF-beta\/SMAD pathway in rats. Mol Biol Rep. 2024;51(1):529.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"5012_CR86","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s12951-024-02613-2","volume":"22","author":"C Ji","year":"2024","unstructured":"Ji C, Zhang J, Shi H, Chen B, Xu W, Jin J, et al. Single-cell RNA transcriptomic reveal the mechanism of MSC derived small extracellular vesicles against DKD fibrosis. J Nanobiotechnol. 2024;22(1):339.","journal-title":"J Nanobiotechnol"},{"issue":"5","key":"5012_CR87","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00281-021-00888-3","volume":"43","author":"J Floege","year":"2021","unstructured":"Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy. Semin Immunopathol. 2021;43(5):717\u201328.","journal-title":"Semin Immunopathol"},{"issue":"11","key":"5012_CR88","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.34067\/KID.0000000000000563","volume":"5","author":"A Tanaka","year":"2024","unstructured":"Tanaka A, Furuhashi K, Fujieda K, Horinouchi A, Maeda K, Saito S, et al. Safety and Tolerability of Adipose-Derived Mesenchymal Stem Cell (ADR-001) Therapy for IgA Nephropathy. Kidney360. 2024;5(11):1692\u2013705.","journal-title":"Kidney360"},{"issue":"10","key":"5012_CR89","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1681\/ASN.0000000000000189","volume":"34","author":"N Perico","year":"2023","unstructured":"Perico N, Remuzzi G, Griffin MD, Cockwell P, Maxwell AP, Casiraghi F, et al. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). J Am Soc Nephrol. 2023;34(10):1733\u201351.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"5012_CR90","doi-asserted-by":"publisher","first-page":"S633","DOI":"10.1016\/j.ekir.2024.11.1128","volume":"10","author":"BS Cho","year":"2025","unstructured":"Cho BS, Jung S, Cho WH, Lee HS, Choi J-Y, Kim Dy, et al. WCN25-482 Mesenchymal Stem Cell might be a rescue therapy in severe IgA nephropathy with CKD. Kidney Int Rep. 2025;10(2):S633\u20134.","journal-title":"Kidney Int Rep"},{"issue":"7","key":"5012_CR91","first-page":"4855","volume":"14","author":"NH Riordan","year":"2022","unstructured":"Riordan NH, Ambrozic RA, Paz-Rodriguez J. Case report: effect of umbilical cord mesenchymal stem cells on immunoglobulin A nephropathy after acute renal failure. Am J Transl Res. 2022;14(7):4855\u20139.","journal-title":"Am J Transl Res"},{"issue":"10","key":"5012_CR92","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","volume":"7","author":"MM Lalu","year":"2012","unstructured":"Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS ONE. 2012;7(10):e47559.","journal-title":"PLoS ONE"},{"issue":"1","key":"5012_CR93","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.stem.2009.05.003","volume":"5","author":"RH Lee","year":"2009","unstructured":"Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell. 2009;5(1):54\u201363.","journal-title":"Cell Stem Cell"},{"issue":"18","key":"5012_CR94","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1097\/CM9.0000000000003768","volume":"138","author":"L Cui","year":"2025","unstructured":"Cui L, Zou H, You S, Guo C, Gu J, Shang Y, et al. Off-the-shelf human umbilical cord mesenchymal stromal cell product in acute-on-chronic liver failure: A multicenter phase I\/II clinical trial. Chin Med J (Engl). 2025;138(18):2347\u20139.","journal-title":"Chin Med J (Engl)"},{"issue":"5701","key":"5012_CR95","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1126\/science.1099513","volume":"306","author":"J Houghton","year":"2004","unstructured":"Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, et al. Gastric cancer originating from bone marrow-derived cells. Science. 2004;306(5701):1568\u201371.","journal-title":"Science"},{"issue":"3","key":"5012_CR96","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/path.2603","volume":"219","author":"AB Mohseny","year":"2009","unstructured":"Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, et al. Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol. 2009;219(3):294\u2013305.","journal-title":"J Pathol"},{"issue":"1","key":"5012_CR97","first-page":"163","volume":"40","author":"S Tsukamoto","year":"2012","unstructured":"Tsukamoto S, Honoki K, Fujii H, Tohma Y, Kido A, Mori T, et al. Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model. Int J Oncol. 2012;40(1):163\u20139.","journal-title":"Int J Oncol"},{"issue":"1","key":"5012_CR98","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s12015-011-9345-4","volume":"9","author":"F Casiraghi","year":"2013","unstructured":"Casiraghi F, Remuzzi G, Abbate M, Perico N. Multipotent mesenchymal stromal cell therapy and risk of malignancies. Stem Cell Rev Rep. 2013;9(1):65\u201379.","journal-title":"Stem Cell Rev Rep"},{"key":"5012_CR99","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.eclinm.2019.100249","volume":"19","author":"M Thompson","year":"2020","unstructured":"Thompson M, Mei SHJ, Wolfe D, Champagne J, Fergusson D, Stewart DJ, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. EClinicalMedicine. 2020;19:100249.","journal-title":"EClinicalMedicine"},{"key":"5012_CR100","first-page":"866","volume":"52","author":"F Wang","year":"2025","unstructured":"Wang F, Li L, Deng J, Mo S, Ai J, Xiao Y, et al. Extruded nanovesicles derived from umbilical cord mesenchymal stem cells exhibit No tumorigenic potential. Bioact Mater. 2025;52:866\u201376.","journal-title":"Bioact Mater"},{"issue":"1","key":"5012_CR101","doi-asserted-by":"publisher","first-page":"e1163","DOI":"10.1002\/ctm2.1163","volume":"13","author":"GJ Marti-Chillon","year":"2023","unstructured":"Marti-Chillon GJ, Muntion S, Preciado S, Osugui L, Navarro-Bailon A, Gonzalez-Robledo J, et al. Therapeutic potential of mesenchymal stromal\/stem cells in critical-care patients with systemic inflammatory response syndrome. Clin Transl Med. 2023;13(1):e1163.","journal-title":"Clin Transl Med"},{"issue":"1","key":"5012_CR102","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-021-01037-x","volume":"14","author":"T Zhou","year":"2021","unstructured":"Zhou T, Yuan Z, Weng J, Pei D, Du X, He C, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol. 2021;14(1):24.","journal-title":"J Hematol Oncol"},{"issue":"7\u20138","key":"5012_CR103","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1089\/ten.tea.2011.0391","volume":"18","author":"BA Aguado","year":"2012","unstructured":"Aguado BA, Mulyasasmita W, Su J, Lampe KJ, Heilshorn SC. Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A. 2012;18(7\u20138):806\u201315.","journal-title":"Tissue Eng Part A"},{"issue":"3","key":"5012_CR104","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1161\/CIRCRESAHA.108.187724","volume":"104","author":"C Toma","year":"2009","unstructured":"Toma C, Wagner WR, Bowry S, Schwartz A, Villanueva F. Fate of culture-expanded mesenchymal stem cells in the microvasculature: in vivo observations of cell kinetics. Circ Res. 2009;104(3):398\u2013402.","journal-title":"Circ Res"},{"key":"5012_CR105","doi-asserted-by":"publisher","first-page":"1239633","DOI":"10.3389\/fpain.2023.1239633","volume":"4","author":"K Ren","year":"2023","unstructured":"Ren K, Vickers R, Murillo J, Ruparel NB. Revolutionizing orofacial pain management: the promising potential of stem cell therapy. Front Pain Res (Lausanne). 2023;4:1239633.","journal-title":"Front Pain Res (Lausanne)"},{"issue":"2\u20133","key":"5012_CR106","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1615\/JLongTermEffMedImplants.2014010946","volume":"24","author":"MA Wagner","year":"2014","unstructured":"Wagner MA, Marks WH, Bhatia SK. Hydrogel encapsulation to improve cell viability during syringe needle flow. J Long Term Eff Med Implants. 2014;24(2\u20133):151\u201362.","journal-title":"J Long Term Eff Med Implants"},{"key":"5012_CR107","doi-asserted-by":"publisher","first-page":"843","DOI":"10.12688\/f1000research.55351.1","volume":"10","author":"IGR Suryawan","year":"2021","unstructured":"Suryawan IGR, Pikir BS, Rantam FA, Ratri AK, Nugraha RA. Hypoxic Preconditioning Promotes Survival of Human Adipose Derived Mesenchymal Stem Cell. F1000Res. 2021;10:843.","journal-title":"F1000Res"},{"key":"5012_CR108","doi-asserted-by":"publisher","first-page":"824752","DOI":"10.3389\/fcell.2022.824752","volume":"10","author":"C Liao","year":"2022","unstructured":"Liao C, Chen G, Yang Q, Liu Y, Zhou T. Potential Therapeutic Effect and Mechanisms of Mesenchymal Stem Cells-Extracellular Vesicles in Renal Fibrosis. Front Cell Dev Biol. 2022;10:824752.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"5012_CR109","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/s13287-021-02447-x","volume":"12","author":"P Nie","year":"2021","unstructured":"Nie P, Bai X, Lou Y, Zhu Y, Jiang S, Zhang L, et al. Human umbilical cord mesenchymal stem cells reduce oxidative damage and apoptosis in diabetic nephropathy by activating Nrf2. Stem Cell Res Ther. 2021;12(1):450.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"5012_CR110","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41392-022-01036-5","volume":"7","author":"Q Yuan","year":"2022","unstructured":"Yuan Q, Tang B, Zhang C. Signaling pathways of chronic kidney diseases, implications for therapeutics. Signal Transduct Target Ther. 2022;7(1):182.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"5012_CR111","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3892\/mmr.2014.2179","volume":"10","author":"J Yao","year":"2014","unstructured":"Yao J, Ke Z, Wang X, Peng F, Li B, Wu R. Epithelial-mesenchymal transition and apoptosis of renal tubular epithelial cells are associated with disease progression in patients with IgA nephropathy. Mol Med Rep. 2014;10(1):39\u201344.","journal-title":"Mol Med Rep"},{"issue":"4","key":"5012_CR112","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1007\/s40620-021-01196-7","volume":"35","author":"Y Caliskan","year":"2022","unstructured":"Caliskan Y, Demir E, Karatay E, Ozluk Y, Mirioglu S, Dirim AB, et al. Oxidative stress and macrophage infiltration in IgA nephropathy. J Nephrol. 2022;35(4):1101\u201311.","journal-title":"J Nephrol"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05012-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05012-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05012-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T01:02:08Z","timestamp":1779152528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05012-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":112,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5012"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05012-6","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"14 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"186"}}